Literature DB >> 7834200

Modulation of 5-HT release in the guinea-pig brain following long-term administration of antidepressant drugs.

P Blier1, C Bouchard.   

Abstract

1. The aims of the present study were to determine whether long-term 5-hydroxytryptamine (5-HT) reuptake blockade and inhibition of type-A monoamine oxidase (MAO-A) lead to an enhancement of the electrically evoked release of tritum from guinea-pig brain slices preloaded with [3H]-5-HT, and to assess the sensitivity of the terminal 5-HT1D autoreceptor, the alpha 2-adrenoceptor also located on 5-HT terminals, and the 5-HT3 receptor that modulates 5-HT release following these two types of antidepressant treatments. 2. The electrically evoked release of tritium was significantly enhanced following a 21-day treatment with the 5-HT reuptake blocker, paroxetine and the reversible MAO-A inhibitor, befloxatone, in preloaded slices of the hypothalamus, hippocampus and frontal cortex 48 h after removal of the osmotic minipumps used to deliver the drugs. 3. The inhibitory effect of the terminal 5-HT autoreceptor agonist, 5-methoxytryptamine, on the evoked release of tritium was attenuated in slices of the hypothalamus, hippocampus, but not frontal cortex, following the paroxetine treatment. In the befloxatone group, the effectiveness of 5-methoxytryptamine was unaltered in the same brain structures. 4. The sensitivity of the alpha 2-adrenoceptor on 5-HT terminals, assessed using UK 14.304, was attenuated in hypothalamus, hippocampus, but not frontal cortex slices prepared from befloxatone-treated guinea-pigs and preloaded with [3H]-5-HT. The paroxetine treatment did not alter the sensitivity of this alpha 2-adrenoceptor in the hypothalamus. 5. The sensitivity of the alpha 2-adrenoceptor on noradrenaline terminals, also assessed using UK 14.304, was not altered in hippocampus and hypothalamus slices preloaded with [3H]-noradrenaline following the long-term befloxatone treatment. 6. In frontal cortex slices, [3H]-5-HT uptake was no longer significantly attenuated after a 21-day treatment with paroxetine, whereas it was still markedly inhibited in hypothalamus slices. The enhancing effect of paroxetine on the evoked release of [3H]-5-HT in the superfusion medium was no longer evident in frontal cortex slices of the paroxetine group. These data indicate that long-term 5-HT reuptake blockade desensitized the 5-HT transporter in the frontal cortex. 7. The capacity of the 5-HT3 receptor agonist, 2 methyl-5-HT, to enhance the electrically evoked release of tritium was not altered in hypothalamus, hippocampus, and frontal cortex slices prepared from befloxatone-treated guinea-pigs, but was significantly attenuated in the paroxetine group also treated for 21 days. Following a 2-day paroxetine treatment, the enhancing effect of 2-methyl-5-HT on tritium release was unaltered in frontal cortex slices.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7834200      PMCID: PMC1510133          DOI: 10.1111/j.1476-5381.1994.tb17015.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  30 in total

1.  5-HT3 receptors which modulate [3H]5-HT release in the guinea pig hypothalamus are not autoreceptors.

Authors:  P Blier; P J Monroe; C Bouchard; D L Smith; D J Smith
Journal:  Synapse       Date:  1993-10       Impact factor: 2.562

Review 2.  Current advances and trends in the treatment of depression.

Authors:  P Blier; C de Montigny
Journal:  Trends Pharmacol Sci       Date:  1994-07       Impact factor: 14.819

3.  Tricyclic antidepressants: long-term treatment increases responsivity of rat forebrain neurons to serotonin.

Authors:  C de Montigny; G K Aghajanian
Journal:  Science       Date:  1978-12-22       Impact factor: 47.728

4.  Desensitization of the neuronal 5-HT carrier following its long-term blockade.

Authors:  G Piñeyro; P Blier; T Dennis; C de Montigny
Journal:  J Neurosci       Date:  1994-05       Impact factor: 6.167

5.  Electrophysiologic evidence for desensitization of alpha 2-adrenoceptors on serotonin terminals following long-term treatment with drugs increasing norepinephrine synaptic concentration.

Authors:  R Mongeau; C de Montigny; P Blier
Journal:  Neuropsychopharmacology       Date:  1994-02       Impact factor: 7.853

6.  In vivo electrophysiological evidence for tonic activation by endogenous noradrenaline of alpha 2-adrenoceptors on 5-hydroxytryptamine terminals in the rat hippocampus.

Authors:  R Mongeau; P Blier; C de Montigny
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-03       Impact factor: 3.000

7.  Regional brain expression of serotonin transporter mRNA and its regulation by reuptake inhibiting antidepressants.

Authors:  K P Lesch; C S Aulakh; B L Wolozin; T J Tolliver; J L Hill; D L Murphy
Journal:  Brain Res Mol Brain Res       Date:  1993-01

8.  Cisapride for the treatment of nausea produced by selective serotonin reuptake inhibitors.

Authors:  R Bergeron; P Blier
Journal:  Am J Psychiatry       Date:  1994-07       Impact factor: 18.112

9.  Chronic fluoxetine treatment upregulates 5-HT uptake sites and 5-HT2 receptors in rat brain: an autoradiographic study.

Authors:  P D Hrdina; T B Vu
Journal:  Synapse       Date:  1993-08       Impact factor: 2.562

10.  Parachlorophenylalanine reversal of tranylcypromine effects in depressed patients.

Authors:  B Shopsin; E Friedman; S Gershon
Journal:  Arch Gen Psychiatry       Date:  1976-07
View more
  18 in total

Review 1.  Sigma receptors: potential targets for a new class of antidepressant drug.

Authors:  James A Fishback; Matthew J Robson; Yan-Tong Xu; Rae R Matsumoto
Journal:  Pharmacol Ther       Date:  2010-05-11       Impact factor: 12.310

2.  Enhancement of Treatment Response in Depression in the Primary Care Setting.

Authors: 
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2004

Review 3.  5-HT(1A) receptor function in major depressive disorder.

Authors:  Jonathan Savitz; Irwin Lucki; Wayne C Drevets
Journal:  Prog Neurobiol       Date:  2009-02-07       Impact factor: 11.685

4.  Long-term antidepressant treatments result in a tonic activation of forebrain 5-HT1A receptors.

Authors:  N Haddjeri; P Blier; C de Montigny
Journal:  J Neurosci       Date:  1998-12-01       Impact factor: 6.167

5.  Enhancement of serotonergic and noradrenergic neurotransmission in the rat hippocampus by sustained administration of bupropion.

Authors:  Ramez Ghanbari; Mostafa El Mansari; Pierre Blier
Journal:  Psychopharmacology (Berl)       Date:  2011-03-29       Impact factor: 4.530

6.  Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level.

Authors:  S Benmansour; M Cecchi; D A Morilak; G A Gerhardt; M A Javors; G G Gould; A Frazer
Journal:  J Neurosci       Date:  1999-12-01       Impact factor: 6.167

7.  Gray matter volumes in obsessive-compulsive disorder before and after fluoxetine or cognitive-behavior therapy: a randomized clinical trial.

Authors:  Marcelo Queiroz Hoexter; Fábio Luis de Souza Duran; Carina Chaubet D'Alcante; Darin Dean Dougherty; Roseli Gedanke Shavitt; Antonio Carlos Lopes; Juliana Belo Diniz; Thilo Deckersbach; Marcelo Camargo Batistuzzo; Rodrigo Affonseca Bressan; Euripedes Constantino Miguel; Geraldo Filho Busatto
Journal:  Neuropsychopharmacology       Date:  2011-10-26       Impact factor: 7.853

8.  Functional characterization of 5-HT1D autoreceptors on the modulation of 5-HT release in guinea-pig mesencephalic raphe, hippocampus and frontal cortex.

Authors:  M el Mansari; P Blier
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

9.  Effect of serotonin on paired associative stimulation-induced plasticity in the human motor cortex.

Authors:  Giorgi Batsikadze; Walter Paulus; Min-Fang Kuo; Michael A Nitsche
Journal:  Neuropsychopharmacology       Date:  2013-05-17       Impact factor: 7.853

10.  Pharmacokinetic-pharmacodynamic modelling of fluvoxamine 5-HT transporter occupancy in rat frontal cortex.

Authors:  M Geldof; J I Freijer; L van Beijsterveldt; X Langlois; M Danhof
Journal:  Br J Pharmacol       Date:  2008-05-19       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.